Anti-tumor activity of the novel angiogenesis inhibitor anginex

Cancer Letters

Volumn 194, Issue 1, 2003, Pages 55-66

  Dings, Ruud P M ^a,b   Van Der Schaft, Daisy W J ^b   Hargittai, Balazs ^a,c   Haseman, Judy ^a   Griffioen, Arjan W ^b   Mayo, Kevin H ^a  

^a University of Minnesota   (United States)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SAINT FRANCIS UNIVERSITY   (United States)

Author keywords

Anginex; Angiogenesis; Bioavailability; Conjugation; Microvessel density; Systemic treatment

Indexed keywords

ANGINEX; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; COLLAGEN GEL; HUMAN SERUM ALBUMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INOCULATION; MICROVASCULATURE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; OSMOTIC MINIPUMP; OVARY CARCINOMA; PRIORITY JOURNAL; XENOGRAFT;

ANIMALIA;

EID: 0347928833     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00015-6     Document Type: Article

References (30)

1. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 52:2000;237-268.
2. Folkman J., Klagsbrun M. Angiogenic factors. Science. 235:1987;442-447.
3. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
4. S.G. Williams, M. Buscarini, J.P. Stein, Molecular markers for diagnosis, staging, and prognosis of bladder cancer, Oncology (Huntingt) 15 (2001) 1469-70, 73-4, 76; discussion 76-84.
5. Weidner N. Angiogenesis as a predictor of clinical outcome in cancer patients. Hum. Pathol. 31:2000;403-405.
6. O'Reilly M.S., Holmgren L., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
7. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
8. Rastinejad F., Polverini P.J., Bouck N.P. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell. 56:1989;345-355.
9. Kusaka M., Sudo K., Fujita T., et al. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem. Biophys. Res. Commun. 174:1991;1070-1076.
10. Gupta S.K., Singh J.P. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression, J. Cell Biol. 127:1994;1121-1127.
11. Onn A., Tseng J.E., Herbst R.S. Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy. Clin. Cancer Res. 7:2001;3311-3313.
12. Sills A.K. Jr., Williams J.I., Tyler B.M., et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res. 58:1998;2784-2792.
13. van der Schaft D.W., Toebes E.A., Haseman J.R., Mayo K.H., Griffioen A.W. Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. Blood. 96:2000;176-181.
14. Kerbel R.S. Tumor angiogenesis: past, present and the near future, Carcinogenesis. 21:2000;505-515.
15. Fogarty M. Learning from angiogenesis trial failures. Scientist. 16:2002;33-35.
16. Griffioen A.W., van der Schaft D.W., Barendsz-Janson A.F., et al. Anginex, a designed peptide that inhibits angiogenesis. Biochem. J. 354:2001;233-242.
17. Kisker O., Becker C.M., Prox D., et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 61:2001;7669-7674.
18. Majumdar M.K., Wang E., Morris E.A. BMP-2 and BMP-9 promotes chondrogenic differentiation of human multipotential mesenchymal cells and overcomes the inhibitory effect of IL-1, J. Cell Physiol. 189:2001;275-284.
19. Duncan R.J., Weston P.D., Wrigglesworth R. A new reagent which may be used to introduce sulfhydryl groups into proteins, and its use in the preparation of conjugates for immunoassay. Anal. Biochem. 132:1983;68-73.
20. Klotz I.M., Heiney R.E. Introduction of sulfhydryl groups into proteins using acetylmercapto succinic anhydride. Arch. Biochem. Biophys. 96:1962;605-612.
21. Elman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82:1959;70-77.
22. Wild R., Ramakrishnan S., Sedgewick J., Griffioen A.W. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc. Res. 59:2000;368-376.
23. Shalinsky D.R., Brekken J., Zou H., et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. N.Y. Acad. Sci. 878:1999;236-270.
24. Takka S., Ocak O.H., Acarturk F. Formulation and investigation of nicardipine HCl-alginate gel beads with factorial design-based studies. Eur. J. Pharm. Sci. 6:1998;241-246.
25. Read T.A., Sorensen D.R., Mahesparan R., et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat. Biotechnol. 19:2001;29-34.
26. Arica B., Calis S., Kas H., Sargon M., Hincal A. 5-Fluorouracil encapsulated alginate beads for the treatment of breast cancer. Int. J. Pharm. 242:2002;267-269.
27. Mehvar R., Robinson M.A., Reynolds J.M. Molecular weight dependent tissue accumulation of dextrans: in vivo studies in rats. J. Pharm. Sci. 83:1994;1495-1499.
28. Yamaoka T., Tabata Y., Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83:1994;601-606.
29. Dosi F., Brusa P., Crosasso P., Arpicco S., Cattel L. Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J. Control. Release. 47:1997;293-304.
30. Bruns C.J., Harbison M.T., Davis D.W., et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 6:2000;1936-1948.